Navigation Links
Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
Date:6/12/2008

al generally associated with currently approved GABAergic drugs. Through its novel mechanism, APD125 has the potential to reduce insomnia symptoms by improving sleep maintenance.

About Insomnia

Insomnia is characterized by inadequate or poor sleep due to nonrefreshing sleep, frequent wakening with difficulty falling back to sleep, difficulty falling asleep or waking too early. Most insomnia complaints relate to sleep maintenance issues, such as waking frequently or awakening too early, as opposed to problems with sleep latency (i.e. falling asleep). Between 30 to 40% of US adults report some level of insomnia and insomnia is a chronic problem for about 10% of the US adult population. The lack of restful sleep may impair the person's ability to carry out their daily responsibilities because they are too tired or have trouble concentrating.

Insomnia has a variety of causes. It is often a symptom of some other disease or condition (e.g. life stress, psychiatric and medical disorders, or use of certain medications), but it can also be a distinct disorder. The prevalence of insomnia increases with age and is more common in women. Common symptoms of acute insomnia are sleepiness, negative mood and impairment of performance. Chronic insomnia is often associated with fatigue, mood changes, difficulty concentrating and impaired daytime functioning.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds target G protein-coupled receptors, an important class of validated drug targets, and includes compounds being evaluated independently and with partners, including Mer
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
2. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
4. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
5. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
6. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
7. Morria Biopharmaceuticals Plc Announces Regulatory Approval to Commence Phase II Clinical Study of MRX-4 in Allergic Rhinitis
8. Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
9. Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
10. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
11. Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 As health officials across the Midwest warn against ... in Michigan will offer free diagnostic ... Meijer pharmacists to administer tests and, in some cases, fill ... participating in the study. The Grand ...
(Date:1/15/2014)...  Celsion Corporation (the "Company") (NASDAQ: CLSN ) ... investors to purchase an aggregate of approximately $15 million ... direct offering, led by a dedicated health care fund. ... with these investors pursuant to which the Company agreed ...
(Date:1/15/2014)... 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will receive ... Journal of Drugs in Dermatology (JDD) at the ... event is January 17-20, 2014, at the Omni Orlando Resort at ... The ODAC is a distinguished event that delivers ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... Jan. 24, 2012 Span-America Medical Systems, Inc. (NASDAQ: ... of its conference call on Friday, February 3, 2012, ... will be released after the regular close of trading ... Span-America,s conference call will be available online at ...
... Group, Inc. (OTCBB: BONU), and Barnabas Health in ... collaborative research and revenue sharing agreement.  The parties ... detergent cleaner, 90-second disinfectant and 20-minute sterilant. In ... rapid cleaning and sterilization of surgical instruments, scopes, ...
Cached Medicine Technology:BioNeutral and Barnabas Health to Collaborate for Surgical Instrument Sterilization 2BioNeutral and Barnabas Health to Collaborate for Surgical Instrument Sterilization 3
(Date:4/17/2014)... Meaningful long-term survival is possible for selected patients ... treated with cytoreductive surgery with Hyperthermic IntraPeritoneal Chemotherapy, ... physicians at Wake Forest Baptist Medical Center. , ... experience with cytoreductive surgery and HIPEC, said lead ... 20 years, worth of patient data shows that ...
(Date:4/17/2014)... Canadians surveyed said they would participate in public health ... genetic conditions, only 80 per cent said they would ... their newborns, genomes.,Most newborns in North America have a ... of life in which a tiny amount of blood ... five to 54 conditions, depending on the state or ...
(Date:4/17/2014)... have called for more research to be carried ... in sub-Saharan Africa. In a paper in ... Stothard, working with colleagues in the department of ... in Cleveland Ohio, University of Cambridge and the ... the joint burden of HIV/AIDS and schistosomiasis of ...
(Date:4/16/2014)... Texas (April 16, 2014) A team that includes scientists ... Health Science Center at San Antonio, Johns Hopkins University and ... helps a common fungus to infect the body. , The ... rashes and oral thrush, and is the most common fungal ...
(Date:4/15/2014)... Handling frozen fish caused nearly half of all ... the injuries on freezer-longliner vessels operating off the coast ... , Many of those injuries and others aboard the ... right interventions, and the research methods used in the ...
Breaking Medicine News(10 mins):Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2Health News:Researcher looks at public perceptions around newborn testing 2Health News:Researcher looks at public perceptions around newborn testing 3Health News:More research called for into HIV and schistosomiasis coinfection in African children 2Health News:Changes in processing, handling could reduce commercial fishing injuries 2
... Diego – Obesity is back in the news with one ... Cancer. People who are obese carry an enhanced risk of ... California, San Diego have unearthed the link between obesity and ... the obese secrete a hormone called leptin, which induces growth ...
... proportions”, a study finding which says that hormone replacement therapy ... of heart disease. , The study published in ... replacement therapy or HRT, taken by women in their 50’s ... attacks and other such conditions. , This finding ...
... a possible herbal cure for urinary track// infection (UTI). ... Center found that the herb called forskalin or ... UTI as well as help antibiotics kill 90 percent of ... and Urologic Diseases Information Clearinghouse (NKUDIC) says urinary tract infections ...
... will soon start an integrated trauma care facility to ... //to patients on way to a hospital from an ... of Physicians of Indian Origin (AAPI), the emergency medical ... fully equipped ambulances within minutes of an accident., ...
... of developing colon cancer, the third most common form of ... body of obese people produce leptin - a hormone that ... a person has, the more leptin will be in their ... Surgery. ,A colon cancer patient suffers from cancerous ...
... US-based ImClone Systems and Bristol-Myers Squibb have announced that ... with platinum-based //chemotherapy have increased survival chances among cancer ... the head and neck (SCCHN). ,Worldwide SCCHN ... head and neck, and approximately two-thirds of all patients ...
Cached Medicine News:Health News:Hormone Replacement Therapy- Not A Fallen Angel 2Health News:Ancient Indian Herb May Prove Cure For Recurrent UTI 2Health News:Integrated Trauma Care Facility in Mumbai 2Health News:Integrated Trauma Care Facility in Mumbai 3Health News:A New Erbitux Combo Shows Promise in treatment 2
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
... precise episcleral, intrascleral, and intraocular hemostasis ... Rf diathermy delivers targeted coagulation with ... Eraser instruments, forceps and cables. This ... a high level of Wet-Field safety ...
Medicine Products: